Page last updated: 2024-11-08

5-fluorotryptamine monohydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID197774
CHEMBL ID1507054
SCHEMBL ID1967285
MeSH IDM0320139

Synonyms (44)

Synonym
1h-indole-3-ethanamine, 5-fluoro-, monohydrochloride
5-fluoro-1h-indole-3-ethanamine monohydrochloride
3-(2-aminoethyl)-5-fluoroindole hydrochloride
indole, 3-(2-aminoethyl)-5-fluoro-, hydrochloride
5-fluoro-1h-indole-3-ethylamine monohydrochloride
einecs 220-307-5
nsc-33245
nsc33245
2711-58-2
MLS000047815 ,
smr000033820
5-fluorotryptamine hydrochloride
F-6500
AKOS001475938
2-(5-fluoro-1h-indol-3-yl)ethanamine hydrochloride
3-(2-aminoethyl)-5-fluoro-1h-indole hydrochloride
2-(5-fluoro-1h-indol-3-yl)ethylamine hydrochloride
5-fluoro-tryptamine hcl
5-fluoro-tryptamine hydrochloride
2-(5-fluoro-1h-indol-3-yl)-1-ethanamine hydrochloride
5-fluorotryptamine hcl
nsc 33245
AM20050351
2-(5-fluoro-1h-indol-3-yl)ethan-1-amine hydrochloride
AKOS015898501
FT-0620430
CHEMBL1507054
SCHEMBL1967285
YZAWADGJXKCLTI-UHFFFAOYSA-N
mfcd00051081
cambridge id 5107368
2-(5-fluoro-1h-indol-3-yl)ethanamine;hydrochloride
PS-7956
OPERA_ID_1414
DTXSID70181572
sr-01000532147
SR-01000532147-1
GS-6536
2-(5-fluoro-1h-indol-3-yl)ethan-1-amine hydrochloridyl
Z1741960310
AS-35972
2-(5-fluoro-1h-indol-3-yl)ethanamine hcl
EN300-195678
PD130002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.03550.003245.467312,589.2998AID2517
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency3.98110.010323.856763.0957AID2662
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency30.54730.060110.745337.9330AID485367; AID504636; AID504637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)EC50 (µMol)2.21900.07001.46505.1000AID718
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.73677.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.00011.46937.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01902.149910.0000AID718
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.73677.0000AID718
GABA theta subunitRattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)EC50 (µMol)2.21900.01901.70547.0000AID718
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]